Malignant mixed neoplasm

Summary

Malignant mixed neoplasm (MONDO:0005853) is a cancer (an umbrella term covering 15 Mondo subtypes). A subtype of cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Umbrella term: 15 Mondo subtypes

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	malignant mixed neoplasm
Mondo ID	MONDO:0005853
EFO	EFO:1000356
MeSH	D018198
DOID	DOID:154
NCIT	C3729
UMLS	C0206625
MedGen	64618
Is cancer (heuristic)	yes

Also known as: malignant mixed neoplasm · malignant mixed tumor · malignant mixed tumors · malignant mixed tumour · malignant mixed tumours · mixed cell type cancer · mixed neoplasm · mixed neoplasm, malignant · mixed tumor · mixed tumor, malignant (morphologic abnormality) · mixed tumor, malignant, NOS (morphologic abnormality) · mixed tumors, malignant · mixed tumour · tumor, malignant mixed · tumor, mixed, malignant · tumors, malignant mixed

Disease family

This is a subtype of cancer. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › malignant mixed neoplasm

Related subtypes (32): respiratory system cancer, immune system cancer, musculoskeletal system cancer, integumentary system cancer, peritoneum cancer, cardiovascular cancer, reproductive system cancer, malignant giant cell tumor, digestive system cancer, lipomatous cancer, thoracic cancer, malignant glomus tumor, malignant mesenchymoma, carcinoma, sarcoma, blastoma, head and neck cancer, nervous system cancer, retroperitoneal cancer, malignant germ cell tumor, malignant mesothelioma, malignant urinary system neoplasm, childhood malignant neoplasm, anaplastic cancer, malignant spindle cell neoplasm, high grade malignant neoplasm, malignant endocrine neoplasm, malignant soft tissue neoplasm, secondary malignant neoplasm, refractory malignant neoplasm, malignant adenoma, cancer of unknown primary site

Subtypes (15): carcinoma ex pleomorphic adenoma, uterine body mixed cancer, carcinosarcoma, adenocarcinofibroma, ovarian seromucinous carcinoma, adenosarcoma, Wilms tumor, combined lung carcinoma, mixed lobular and ductal breast carcinoma, gonadoblastoma, anaplastic oligoastrocytoma, malignant mixed epithelial stromal tumor of the kidney, malignant phyllodes tumor, malignant vaginal mixed epithelial and mesenchymal neoplasm, adenoacanthoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

No approved or late-stage (phase ≥3) drug is indicated for this disease; the following are in earlier-phase trials only.

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Carboplatin, Paclitaxel.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.